VistaGen Therapeutics, Inc. (VTGN)
VTGN moved a median of +0.16% 30 minutes after news, and +0.33% by the close. How VTGN actually reacts to news — the realized, point-in-time move the market made, measured across 658 labeled events over the last three years with zero look-ahead.
VTGN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.12% | 42% | 651 |
| 30-min | +0.16% | 52% | 657 |
| 60-min | -0.06% | 47% | 657 |
| to close | +0.33% | 54% | 656 |
| Middle 50% of VTGN reactions | -1.39% to +1.39% |
|---|---|
| Median reaction (30-min) | +0.16% |
| Measured reactions | 658 |
Half of all VistaGen Therapeutics, Inc. news events land between -1.39% and +1.39% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when VTGN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VTGN's baseline. Nothing else.
Recent VTGN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Vistagen Therapeutics, For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | -1.14% | -3.98% | |
| Form 8-K Vistagen Therapeutics, For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | +0.52% | -3.81% | |
| Form 8-K Vistagen Therapeutics, For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | -4.58% | -15.47% | |
| Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder | Press release | GlobeNewswire | -4.58% | -15.47% | |
| Form 8-K Vistagen Therapeutics, For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | +6.76% | -4.58% | |
| Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder | Press release | GlobeNewswire | +5.69% | +2.19% | |
| Form 8-K Vistagen Therapeutics, For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | -1.29% | -1.21% | |
| Vistagen to Present at Psych Congress 2026 | Press release | GlobeNewswire | +0.67% | +0.42% | |
| Form 10-Q Vistagen Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.19% | -3.70% | |
| Form 8-K Vistagen Therapeutics, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -1.63% | -0.89% | |
| Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update | Press release | GlobeNewswire | -1.63% | -0.89% | |
| Form 8-K Vistagen Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -1.78% | +0.14% | |
| Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder | Press release | GlobeNewswire | +0.03% | -4.44% | |
| Form 8-K Vistagen Therapeutics, For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +0.03% | -4.44% | |
| Form 8-K Vistagen Therapeutics, For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | -1.07% | -1.15% | |
| Form DEF 14A Vistagen Therapeutics, For: Jul 31 | SEC filing · Form DEF | SEC EDGAR | -3.16% | -2.00% | |
| Form DEFA14A Vistagen Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -3.16% | -2.00% | |
| Vistagen Appoints Douglas J. Williamson to its Board of Directors | Press release | GlobeNewswire | -1.07% | -1.15% | |
| Form 8-K Vistagen Therapeutics, For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +0.91% | +7.62% | |
| Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder | Press release | Business Wire | +0.91% | +7.62% | |
| Form 8-K Vistagen Therapeutics, For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +4.03% | -3.15% | |
| Form 10-K Vistagen Therapeutics, For: Mar 31 | SEC filing · Form 10-K | SEC EDGAR | -3.43% | +18.97% | |
| Form 8-K Vistagen Therapeutics, For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | -3.43% | +18.97% | |
| Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | Press release | Business Wire | -3.43% | +18.97% | |
| Form 8-K Vistagen Therapeutics, For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -0.83% | -0.91% | |
| Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder | Press release | Business Wire | +0.95% | -1.23% | |
| Vistagen to Participate in Jefferies 2026 Global Healthcare Conference | Press release | Business Wire | -0.92% | -3.98% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +1.13% | +6.04% | |
| Form 8-K Vistagen Therapeutics, For: May 18 | SEC filing · Form 8-K | SEC EDGAR | -1.97% | +1.56% | |
| Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer | Press release | Business Wire | -3.67% | +4.62% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -2.32% | -5.45% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.52% | -3.83% | |
| Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference | Press release | Business Wire | -1.48% | +0.09% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.60% | -1.30% | |
| Form 8-K Vistagen Therapeutics, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -5.34% | +0.02% | |
| Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder | Press release | Business Wire | -5.34% | +0.02% | |
| Form 8-K Vistagen Therapeutics, For: May 08 | SEC filing · Form 8-K | SEC EDGAR | +0.43% | +10.43% | |
| Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder | Press release | Business Wire | +0.13% | +2.19% | |
| Vistagen Therapeutics, Inc. (VTGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.47% | -1.53% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.62% | -0.42% | |
| Form 8-K Vistagen Therapeutics, For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | -1.34% | +1.34% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.37% | -4.18% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +2.18% | -1.98% | |
| Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause | Press release | Business Wire | -2.67% | +0.40% | |
| Vistagen Therapeutics, Inc. (VTGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | — | -0.51% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.64% | -3.03% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.46% | +1.65% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.35% | +0.05% | |
| Form 8-K Vistagen Therapeutics, For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | +2.12% | +1.70% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +2.35% | +4.16% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VTGN section they belong to.
Where else VTGN is measured.
VTGN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Gritstone bio, Inc. (GRTS) | 659 | -0.01% | 50% |
| Inovio Pharmaceuticals, Inc. (INO) | 658 | -0.29% | 43% |
| Quanterix Corporation (QTRX) | 657 | -0.21% | 46% |
| Encompass Health Corporation (EHC) | 656 | +0.01% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is VistaGen Therapeutics, Inc.'s median reaction calculated?
Every labeled VTGN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 658 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of VTGN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VTGN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.